91 related articles for article (PubMed ID: 11991662)
1. Receptor-bound uPA is reversibly protected from inhibition by low molecular weight inhibitors.
Dyer KD; Linz-Mcgillem LA; Alliegro MA; Alliegro MC
Cell Biol Int; 2002; 26(4):327-35. PubMed ID: 11991662
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor.
Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA
Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419
[TBL] [Abstract][Full Text] [Related]
3. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Jankun J; Skrzypczak-Jankun E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
[TBL] [Abstract][Full Text] [Related]
5. High urokinase expression contributes to the angiogenic properties of endothelial cells derived from circulating progenitors.
Basire A; Sabatier F; Ravet S; Lamy E; Mialhe A; Zabouo G; Paul P; Gurewich V; Sampol J; Dignat-George F
Thromb Haemost; 2006 Apr; 95(4):678-88. PubMed ID: 16601839
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA).
Matthews H; Ranson M; Tyndall JD; Kelso MJ
Bioorg Med Chem Lett; 2011 Nov; 21(22):6760-6. PubMed ID: 21978672
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-type plasminogen activator.
Crippa MP
Int J Biochem Cell Biol; 2007; 39(4):690-4. PubMed ID: 17118695
[TBL] [Abstract][Full Text] [Related]
8. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice.
Jankun J; Keck RW; Skrzypczak-Jankun E; Swiercz R
Cancer Res; 1997 Feb; 57(4):559-63. PubMed ID: 9044824
[TBL] [Abstract][Full Text] [Related]
10. Involvement of urokinase-type plasminogen activator in sphingosylphosphorylcholine-induced angiogenesis.
Piao YJ; Lee CH; Zhu MJ; Kye KC; Kim JM; Seo YJ; Suhr KB; Park JK; Kim CD; Lee JH
Exp Dermatol; 2005 May; 14(5):356-62. PubMed ID: 15854129
[TBL] [Abstract][Full Text] [Related]
11. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
Whitley BR; Church FC
Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
[TBL] [Abstract][Full Text] [Related]
12. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view.
Binder BR; Mihaly J; Prager GW
Thromb Haemost; 2007 Mar; 97(3):336-42. PubMed ID: 17334498
[TBL] [Abstract][Full Text] [Related]
13. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
14. A comparison of two controlled-release delivery systems for the delivery of amiloride to control angiogenesis.
Knoll A; Schmidt S; Chapman M; Wiley D; Bulgrin J; Blank J; Kirchner L
Microvasc Res; 1999 Jul; 58(1):1-9. PubMed ID: 10388598
[TBL] [Abstract][Full Text] [Related]
15. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
16. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
[TBL] [Abstract][Full Text] [Related]
17. Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases.
Kim MH
J Cell Biochem; 2003 Jun; 89(3):529-38. PubMed ID: 12761886
[TBL] [Abstract][Full Text] [Related]
18. Urokinase plasminogen activator (uPA) is a positive regulator of outer root sheath keratinocyte proliferation.
Cui ZH; Yang T; Gao QG; Wang Y
Cell Biol Int; 2004; 28(8-9):571-5. PubMed ID: 15350591
[TBL] [Abstract][Full Text] [Related]
19. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
[TBL] [Abstract][Full Text] [Related]
20. Effect of a synthetic inhibitor of urokinase plasminogen activator on the migration and invasion of human cervical cancer cells in vitro.
Wang X; Jiang Z; An J; Mao X; Lin F; Sun P
Mol Med Rep; 2018 Mar; 17(3):4273-4280. PubMed ID: 29328476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
